Skip to main content
. 2022 Mar 19;25:78–97. doi: 10.1016/j.omto.2022.03.008

Table 2.

Clinical trials on the use of MSC-OV in cancer patients

Identifier Status Description/results Reference
EudraCT no. 2008-000364-16 ended prematurely
  • -

    trial to determine the toxicity and clinical outcome of infusion of autologous MSCs infected with the oncolytic adenovirus ICOVIR5 (CELYVIR) in children with refractory or recurrent metastatic solid tumors

 ClinicalTrialsRegister.eu110
  • -

    results not posted

NCT01844661 completed
  • -

    phase I/II trial

 Ruano et al.35
  • -

    evaluation of the safety and clinical response of weekly (n = 6) infusions of CELYVIR in children and adults with metastatic and refractory solid tumors

  • -

    well-tolerated treatment, with only mild toxicity, with potential to achieve clinical responses in patients with advanced tumors

NCT02068794 ongoing
  • -

    phase I/II trial

 ClinicalTrials.gov. National Library of Medicine (USA)111
  • -

    studies side effects and best dose of oncolytic measles virus encoding thyroidal sodium iodide symporter (MV-NIS)-infected MSCs in patients with ovarian, primary peritoneal, and fallopian tube cancer

  • -

    results not posted

NCT03896568 ongoing
  • -

    phase I trial

 ClinicalTrials.gov. National Library of Medicine (USA),112 Chen et al.113
  • -

    studies the best dose and side effects of the intra-arterial administration of oncolytic adenovirus DNX-2401-loaded hBM-MSCs in treating patients with recurrent high-grade glioma

  • -

    utilization of perfusion-guided endovascular super-selective intra-arterial injections enhances the targeting ability of therapeutic delivery to brain tumors

  • -

    trial results not posted

EudraCT no. 2019-001154-26 ongoing
  • -

    studies the feasibility of the combination of AloCELYVIR with chemotherapy and radiotherapy for the treatment of children and adolescents with relapsed or refractory extracranial solid tumors

 ClinicalTrialsRegister.eu114
  • -

    results not posted

NCT05047276 not yet recruiting
  • -

    phase I/II clinical trial

 ClinicalTrials.gov. National Library of Medicine (USA)115
  • -

    studies safety and efficacy parameters of AloCELYVIR in uveal melanoma patients with hepatic metastases